Abstract
Non-small cell lung cancer (NSCLC) metastatic to the brain leptomeninges is rapidly fatal, cannot be biopsied, and cancer cells in the cerebrospinal fluid (CSF) are few; therefore, available tissue samples to develop effective treatments are severely limited. This study aimed to converge single-cell RNA-seq and cell-free RNA (cfRNA) analyses to both diagnose NSCLC leptomeningeal metastases (LM), and to use gene expression profiles to understand progression mechanisms of NSCLC in the brain leptomeninges. NSCLC patients with suspected LM underwent withdrawal of CSF via lumbar puncture. Four cytology-positive CSF samples underwent single-cell capture (n = 197 cells) by microfluidic chip. Using robust principal component analyses, NSCLC LM cell gene expression was compared to immune cells. Massively parallel qPCR (9216 simultaneous reactions) on human CSF cfRNA samples compared the relative gene expression of patients with NSCLC LM (n = 14) to non-tumor controls (n = 7). The NSCLC-associated gene, CEACAM6, underwent in vitro validation in NSCLC cell lines for involvement in pathologic behaviors characteristic of LM. NSCLC LM gene expression revealed by single-cell RNA-seq was also reflected in CSF cfRNA of cytology-positive patients. Tumor-associated cfRNA (e.g., CEACAM6, MUC1) was present in NSCLC LM patients’ CSF, but not in controls (CEACAM6 detection sensitivity 88.24% and specificity 100%). Cell migration in NSCLC cell lines was directly proportional to CEACAM6 expression, suggesting a role in disease progression. NSCLC-associated cfRNA is detectable in the CSF of patients with LM, and corresponds to the gene expression profile of NSCLC LM cells. CEACAM6 contributes significantly to NSCLC migration, a hallmark of LM pathophysiology.
Highlights
Patients with non-small cell lung cancer (NSCLC) are at high risk of developing leptomeningeal brain metastases (LM), where diffuse metastatic cancer growth on the surface of the brain and cranial nerves is rapidly fatal[1]
Parallel qPCR of cell-free RNA (cfRNA) in patient cerebrospinal fluid (CSF) identifies NSCLC LMspecific gene expression To identify NSCLC LM-associated cfRNA in patient CSF, we created a panel of lung and brain-specific genes for parallel qPCR (Supplementary Fig. 1)
Expanding to cfRNA, as a proof of principle we hypothesized that NSCLC LM cells would still preserve some RNA expression features of the primary lung cells from which they originated
Summary
Patients with non-small cell lung cancer (NSCLC) are at high risk of developing leptomeningeal brain metastases (LM), where diffuse metastatic cancer growth on the surface of the brain and cranial nerves is rapidly fatal[1]. The relative rarity of cases, poor prognosis, and lack of tissue available for research have stymied LM research to understand mechanisms of progression and develop new treatments. We previously demonstrated that brain tumor-associated cellfree DNA (cfDNA) in cerebrospinal fluid (CSF) can be used to detect LM and track its response to therapy and relapse[6,7]. This method is reliable and clinically relevant, enabling the detection of tumor-specific mutations in CSF that direct therapy (e.g., EGFR, BRAF) even in patients with no measurable systemic disease.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
